← All trials
NCT02765217
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 1, 2016
- Primary completion
- Jun 1, 2017
- Completion date
- Jun 1, 2018
- First posted
- —
- Last posted
- —
- Enrollment
- 1440
- Arms / groups
- 4 / —
- Source
- AACT · pre-existing
Sponsors
- Eskisehir Osmangazi UniversityLead sponsor
- Eskisehir Osmangazi UniversityReponsible party - principal investigator
- Hacettepe UniversityCollaborator
- Umraniye Education and Research HospitalCollaborator
- Yuzuncu Yıl UniversityCollaborator
- Erzurum Regional Training & Research HospitalCollaborator
- Ege UniversityCollaborator
- Goztepe Training and Research HospitalCollaborator
- Namik Kemal UniversityCollaborator
- Okmeydani Hospital IstanbulCollaborator
- Bezmialem UniversityCollaborator
- Sisli Hamidiye Etfal Training and Research HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.